- García-Heredia, J. M.
- Ortega-Campos, Sara M.
- Carnero, Amancio
[Data availability] Availability of data and materials All datasets analysed in this study are publicly available. Breast cancer datasets from the Gene Expression Omnibus (GEO, RRID:SCR_005012), including GSE69031, GSE21653, GSE1456, GSE20685, GSE25066, GSE42568, GSE162228, and GSE12093, were used in this study and are publicly available at GEO [78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93]. TCGA-BRCA RNA-seq isoform expression and clinical data were obtained from the NCI Genomic Data Commons (GDC; RNA-seq Level 3 RSEM isoform-normalized data dated 2015–08-06). CCLE expression data were obtained from the Cancer Cell Line Encyclopedia (CCLE; RNA-seq transcript TPM file dated 2018–09-29), and drug-response data were integrated with GDSC (release dated 2023–10-27) after harmonising cell-line identifiers. Breast PDX isoform quantifications and metadata were obtained from the PDMR resource. Key analysis outputs and sample-level annotations, including transcript-level differential expression, pathway enrichment results, metabolic expression matrices, drug-response statistics, and NUMB-score assignments, are provided in the Supplementary Information files (Additional file 3: Tables S2–S10). All custom scripts used for data processing and analysis are publicly available at GitHub (https://github.com/jmgheredia/NUMB-tumoral-switch) and are distributed under an OSI-compliant open-source license (MIT License) [111]. The source code has also been permanently archived in Zenodo with an assigned DOI (https://doi.org/10.5281/zenodo.18522980) [112]., [Background] Emerging evidence indicates that cancer is associated with widespread splicing alterations that generate tumour-specific isoforms. One example is NUMB, an evolutionarily conserved adaptor protein, which produces four isoforms (p72, p71, p66, and p65) through alternative splicing of exons 3 and 9. Although traditionally considered as a tumour suppressor, NUMB has also been reported as an oncogene. We propose that this dual role reflects isoform-specific expression., [Results] Using public databases, we identify a tumour-associated switch in NUMB isoform expression: p72 and p71 are upregulated in tumours, whereas p66 and p65 are more highly expressed in non-tumour tissues. These isoforms show distinct associations with key cellular processes. NUMBL, a NUMB homolog, displays expression patterns similar to p65. We further identify two transcriptional clusters: one characterised by high expression of p72 and p71, and the other by enhanced p66/p65/NUMBL expression. These clusters exhibit differential associations with Notch, WNT/β-catenin, Hedgehog, and Hippo signalling pathways, suggesting isoform-specific regulatory roles. In breast cancer cell lines, we develop a NUMB-score based on isoform expression, which classifies cell lines into biologically distinct groups. The p72/p71-enriched group shows distinct signatures, pathway activity, and drug sensitivity. Application of this score to TCGA-BRCA samples reveals a significant link between high NUMB-score and poor survival, as confirmed by Kaplan–Meier analysis., [Conclusions] We find that NUMB emerges as a potential oncogenic contributor and biomarker in the context of splicing-based precision oncology, highlighting Isoform-specific expression as a clinical determinant of tumour behaviour, pathway activity, and therapeutic response., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This research was supported by grants from Ministerio de Ciencia, Innovación y Universidades (MCIU) Plan Estatal de I + D + I 2018, Agencia Estatal de Investigación (AEI) and Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): PID2024-155394OB-I00 and PID2021-122629OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”, by the “European Union”; AEI-MICIU/FEDER (iDIFFER network: RED2024-153635-T). Additional grants from CIBER de Cáncer (CB16/12/00275), from Consejeria de Salud (PI-0397–2017) and Projects P18-RT-2501; and DGP_PIDI_2024_00907 from the Regional Ministry of Economic Transformation, Industry, Knowledge and Universities. Junta de Andalucía. Special thanks to the AECC (Spanish Association of Cancer Research) Founding Ref. GC16173720CARR for supporting this work., Peer reviewed